Lincoln Pharmaceuticals Ltd - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mansi Munjal Patel & PACs Lincoln Pharmaceuticals Ltd - 531633 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kailashben Mahendrabhai Patel, Mahendrabhai Gulabdas Patel & Munjal Mahendrabhai Patel Lincoln Pharmaceuticals Ltd - 531633 - Closure of Trading Window
for closure of trading window. Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Appointment Of CFO And Secretarial Auditors Of The Company.
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/03/2019 ,inter alia, to consider and approve appointment of CFO and Secretarial Auditors of the Company. LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kailashben Mahendrabhai Patel, Mahendrabhai Gulabdas Patel & Munjal Mahendrabhai Patel Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Credit Rating
Lincoln Pharmaceuticals Limited has informed the Exchange regarding Credit Rating. LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding Loss of duplicate Share certificate pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015 LINCOLN PHARMACEUTICALS LTD. - 531633 - Results-Financial Result For Quarter And Nine-Months Ended On December 31, 2018.
has considered and approved the Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine-Months Ended on December 31, 2018. LINCOLN PHARMACEUTICALS LTD. - 531633 - Outcome of Board Meeting
has considered and approved the Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine-Months Ended on December 31, 2018. Lincoln Pharmaceuticals Ltd - 531633 - Closure of Trading Window
for inter-alia to consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Nine-Months Ended on December 31, 2018 along with any other business, if any.